We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Point-of-Care Device Compared for Cardiac Troponin Assay

By LabMedica International staff writers
Posted on 02 Oct 2013
A fingerstick point-of-care (POC) testing for cardiac troponin I has been compared to conventional venipuncture POC testing. More...


Cardiac troponin assays commonly exceed one hour while point-of-care testing can be completed in minutes by basic life support personnel so when patients present complaining of chest pain, time can be critical to achieving positive outcomes.

Scientists at the Loyola University Medical Center (Maywood, IL, USA) collected fingerstick blood samples from consenting patients for whom standard-of-care venipuncture POC troponin (POCT) testing had been ordered as part of their workup. Cardiac troponin (cTnl) assays were performed using a commercial device from June to August 2011. Eighty-nine cTnI levels were measured by both fingerstick and standard venipuncture emergency department POC testing. Four resulted in cartridge error so only the remaining 85 were analyzed.

Cardiac troponin I (cTnI) assays were performed using an i-STAT 1 device (Abbott Point of Care; Princeton, NJ, USA). Fingerstick testing, compared with standard ED POCT, has a positive predictive value of 1.00 (0.48, 1.00), a negative predictive value of 0.96 (0.89, 0.99), a sensitivity of 0.625 (0.24, 0.91), and a specificity of 1.00 (0.95, 1.00). The relationship between methods appeared to be linear.

The authors concluded that fingerstick cTnI testing using the i-STAT device is not accurate enough to determine the exact troponin level without the application of a corrective term. Fingerstick testing is, however, accurate in qualifying troponin levels as negative, borderline, or positive and is, therefore, capable of providing clinical information that may guide diagnostic and therapeutic decision-making. The study was published in the August 2013 issue of the American Journal of Emergency Medicine.

Related Links:
Loyola University Medical Center
Abbott Point of Care



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Repetitive Pipette
VWR® Stepper Pro
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.